Receipt of R&D Tax Incentive payment Antisense Therapeutics Limited (“ANP” or “the Company”) would like to advise that the Company has received from the Australian Taxation Office an R&D Tax Incentive refund payment of $284,900 in relation to expenditure incurred on eligible R&D activities for the 30 June 2018 financial year. A higher amount is anticipated for the following year in line with the greater R&D spend associated with the ongoing clinical trial of ATL1102 in DMD.
Ann: Receipt of R&D Tax Incentive payment, page-2
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.008(8.25%) |
Mkt cap ! $94.66M | |||
| Open | High | Low | Value | Volume |
| 9.8¢ | 11.0¢ | 9.8¢ | $360.4K | 3.457M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 248759 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| PER (ASX) Chart |